Finland Pharmaceuticals & Healthcare Report

Published 10 June 2015

  • 72 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Finland Pharmaceuticals & Healthcare Report

BMI View: Finland ' s growing and ageing population will drive pharmaceutical demand. Despite being relatively small in size compared to some of its Western European counterparts, the market is boosted by high GDP per-capita, ensuring continued spending on high-value drugs in the medium - term. However, rising healthcare costs will place a heavy burden on government finances, requiring patented drug makers to prove the cost-effectiveness of their medicines over less expensive generic drugs.

Headline Expenditure Projections

  • Pharmaceuticals: EUR3.04bn (USD4.08bn) in 2014 to EUR3.10bn (USD3.41bn) in 2015;+1.9% in local currency terms and -16.4% in US dollar terms. Forecast in line with last quarter .

  • Healthcare: EUR18.88bn (USD25.30bn) in 2014 to EUR19.63bn (USD21.59bn) in 2015; +4% in local currency terms and -14.7% in US dollar terms. Forecast revised upwards from last quarter.

Risk/Reward Index

Finland's Risk/Reward Index score is unchanged from last quarter at 68.8 out of 100. This places the country seventh in our index in terms of attractiveness to investors, just above Denmark (68.1) and Belgium (68.0). Finland's strong emphasis on the regulatory environment is an appealing feature of the market, although a major factor affecting the business environment for drugmakers is its small overall market size. Combined with increasing cost-containment measures, this negatively affects the industry rewards score in particular. Nevertheless, high per capita drug expenditure means that companies operating in the country can see substantial incomes.

Key Trends And Developments

May 2015

  • The Finnish city of Oulu has one of the worlds' most advanced e-health programmes which has helped the city overcome healthcare inflation. The digital platform which was introduced in 2008 enables patients to make appointments, refill prescriptions and exchange messages with doctors from their home computers. The system, called Self Care, now caters to around 70,000...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Industry Forecast
13
Pharmaceutical Market Forecast
13
Table: Pharmaceutical Sales, Historical Data And Forecasts (Finland 2011-2019)
14
Healthcare Market Forecast
15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Finland 2011-2019)
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Finland 2011-2019)
17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Finland 2011-2019)
17
Prescription Drug Market Forecast
18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Finland 2011-2019)
19
Patented Drug Market Forecast
20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Finland 2011-2019)
21
Generic Drug Market Forecast
22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Finland 2011-2019)
23
OTC Medicine Market Forecast
24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Finland 2011-2019)
25
Pharmaceutical Trade Forecast
26
Table: Pharmaceutical Trade Data And Forecasts (Finland 2013-2019)
27
Table: Pharmaceutical Trade Data And Forecasts local currency (Finland 2013-2019)
27
Key Risks To BMI's Forecast Scenario
28
Macroeconomic Forecasts
29
Economic Analysis
29
Table: GDP By Expenditure (Finland 2012-2019)
31
Industry Risk Reward Index
32
Western Europe Risk/Reward Index
32
Finland Risk/Reward Index
36
Rewards
36
Risks
37
Market Overview
38
Industry Trends And Developments
39
Industry Trends And Developments
39
Epidemiology
39
Health Insurance
42
Table: Healthcare Resources (Finland 2009-2014)
45
Table: Healthcare Personnel (Finland 2009-2014)
45
Table: Healthcare Activity (Finland 2009-2014)
46
Research & Development
46
Clinical Trials
47
Regulatory Development
49
Pricing & Reimbursement
51
Intellectual Property
54
Competitive Landscape
56
Table: PIF Members
58
Company Developments
58
Demographic Forecast
60
Table: Population Headline Indicators (Finland 1990-2025)
61
Table: Key Population Ratios (Finland 1990-2025)
61
Table: Urban/Rural Population & Life Expectancy (Finland 1990-2025)
62
Table: Population By Age Group (Finland 1990-2025)
62
Table: Population By Age Group % (Finland 1990-2025)
63
Glossary
65
Methodology
67
Pharmaceutical Expenditure Forecast Model
67
Healthcare Expenditure Forecast Model
67
Notes On Methodology
68
Risk/Reward Index Methodology
69
Index Overview
70
Table: Pharmaceutical Risk/Reward Index Indicators
70
Indicator Weightings
71

The Finland Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Finland Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Finland pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Finland, to test other views - a key input for successful budgeting and strategic business planning in the Finnish pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Finnish pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Finland.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc